Home | Structured Search | Drug Resource
Find: within
Cellulitis and Soft Tissue Infections > Drug Therapy Author: Dennis L. Stevens, PhD, MD; Lawrence J. Eron, MD, FACP
Editorial changes - 2008-10-27
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Mild, uncomplicated cellulitis should be treated out of the hospital with oral antibiotics, although it may require surgical drainage which can also be done on an outpatient basis.
  • Moderate to severe cellulitis may require hospitalization for observation, surgery, control of comorbidities, and parenteral antibiotics.
  • Parenteral antibiotics can be provided at home or in an infusion clinic if the patient is compliant to therapy and the cellulitis is not too severe.

Evidence:

  • Classification schemes for cellulitis and soft tissue infection have been reported to assist in treatment decisions (27; 48).
  • According to some studies, abscesses <5 cm in diameter may be effectively treated by incision and drainage without the need for systemic antimicrobial therapy (18; 64; 65). More recent studies show no correlation between the size of the abscesses and the relative need for concordant antibiotic therapy (66). Non-purulent cellulitis may be treated with β-lactam antibiotics, lacking activity against MRSA (67). Purulent cellulitis may require antimicrobial agents with activity against MRSA.

Comments:

  • Non-purulent cellulitis is usually caused by streptococci, and purulent cellulitis by S. aureus.
  • Treatment failure may be due to resistance to the antimicrobial agent, a deeper undrained abscess, or complicating comorbidities such as chronic venous insufficiency or arterial insufficiency.
  • In some patients cutaneous inflammation worsens during the initial 24 hours after antimicrobials are begun. This is not necessarily a sign of failure and may merely represent continued local inflammation due to the release of bacterial antigens from antimicrobial activity (18). Anti-inflammatory agents may accelerate resolution of the clinical signs of inflammation (68; 69; 70).

FAQs
Dennis L. Stevens, PhD, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lawrence J. Eron, MD, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.